Gland Pharma Ltd

Stage 2 · Advancing · week 19Setup 6.5 ★★ GoodStrong +7.2

As of 9 Oct 2026, Gland Pharma is in Stage 2 — advancing, the uptrend phase, in week 19 (since 29 May 2026). It closed at ₹3,062, 2.8% below its 52-week high and above its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. More about the company

₹3,061.8
-0.56% today
₹50,523 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

6.5 ★★ Good

Momentum

Steady

Edge

Strong +7.2

Setup-score rank among Stage 2 peers: #15 of 61 in Pharmaceuticals · #17 of 78 in Health Care

Is GLAND early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-2.8%
₹1,596.8 lo₹3,150.6 hi
2.8% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 19
1w13w26w
Week 19 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
40.4%
200 DMA: ₹2,181.4 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.25x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +1.0% vs MA50 +7.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+3.5%
3M
+23.5%
6M
+77.1%
YTD
+81.5%
1Y
+53.7%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
This stock ranks #17 of 74 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #14 of 58 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-13 → 2026-10-09
S2 15w
S2 17w
S4 20w
S2 15w
S2 19w
2023-07-132026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 4w → S1 4w → S2 10w → S3 2w → S2 15w → S3 12w → S2 17w → S3 2w → S4 11w → S1 4w → S4 20w → S1 3w → S2 15w → S3 11w → S4 6w → S1 6w → S4 7w → S1 1w → S2 19w current
Total tracked: 169 weeks across 19 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-05-29
3 appearances in last 60 days. First seen: 2024-06-06.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 19 · Vol 0.25x
2026-10-08S2
Wk 19 · Vol 0.70x
2026-10-07S2
Wk 19 · Vol 1.97x
2026-10-06S2
Wk 19 · Vol 0.55x
2026-10-05S2
Wk 18 · Vol 0.37x
2026-10-01S2
Wk 18 · Vol 0.48x
2026-09-30S2
Wk 18 · Vol 0.78x
2026-09-29S2
Wk 18 · Vol 1.32x
2026-09-28S2
Wk 18 · Vol 0.33x
2026-09-25S2
Wk 17 · Vol 0.18x
2026-09-24S2
Wk 17 · Vol 0.48x
2026-09-23S2
Wk 17 · Vol 0.23x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
SHILPAMED
wk 22 · -4.8% from hi
7.6
Moving averages & range
50 DMA
₹2,864.8
200 DMA
₹2,181.4
52W High
₹3,150.6
52W Low
₹1,596.8
5D Low
₹2,911.5
Resistance levels (recent highs)
20d High
₹3,150.6
60d High
₹3,150.6
120d High
₹3,150.6
250d High
₹3,150.6
Next resistance
+2.9%
to 20d High
Ask the Market AI about GLANDAsk →
P/E (TTM)
37.1
Forward 25.4
Earnings Growth (YoY)
+96.4%
Revenue +22.3%
ROE
+10.5%
Profit margin +16.0%
Dividend Yield
0.87%
P/B 4.0
About this companyHealth Care· Pharmaceuticals

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.